

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold or transferred** all your shares in **Union Medical Healthcare Limited**, you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



**Union Medical Healthcare Limited**  
**香港醫思醫療集團有限公司\***  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2138)**

**(1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND  
REPURCHASE SHARES;**  
**(2) PROPOSED RE-ELECTION AND ELECTION OF DIRECTORS;  
AND**  
**(3) NOTICE OF ANNUAL GENERAL MEETING**

---

A notice convening the annual general meeting of the Company to be held at Level 53, Langham Place Office Tower, 8 Argyle Street, Mong Kok, Hong Kong on Monday, 20 August 2018 at 10:00 a.m. is set out on pages 15 to 19 of this circular. A form of proxy for use at the annual general meeting is enclosed with this circular. Such form of proxy is also published on the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk).

Whether or not you are able to attend the annual general meeting, you are requested to complete the accompanying form of proxy, in accordance with the instructions printed thereon and deposit the same at the Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the annual general meeting or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the annual general meeting or any adjournment thereof should you so wish.

\* For identification purpose only

# CONTENTS

	<i>Page</i>
<b>Definitions</b> .....	1
<b>Letter from the Board</b> .....	3
Introduction .....	3
Proposed Granting of General Mandates to issue and repurchase Shares .....	4
Proposed Re-election and Election of Directors .....	4
AGM and Proxy Arrangement .....	5
Recommendation .....	5
Responsibility Statement .....	6
General .....	6
<b>Appendix I — Explanatory statement</b> .....	7
<b>Appendix II — Details of Directors proposed to be re-elected                     and elected at the AGM</b> .....	10
<b>Notice of AGM</b> .....	15

## DEFINITIONS

*In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:*

“AGM”	the annual general meeting of the Company to be convened and held on Monday, 20 August 2018 at 10:00 a.m. to consider and, if thought fit, approve, among other things, the proposed grant of the Issuing Mandate (including the extended Issuing Mandate) and the Repurchase Mandate and the proposed re-election and election of Directors
“Article(s)” or “Articles of Association”	the articles of association of the Company
“Board”	the board of directors
“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Company”	Union Medical Healthcare Limited, a company incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on the Main Board of the Stock Exchange
“core connected person”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	the director(s) of the Company
“General Mandates”	the Issuing Mandate and the Repurchase Mandate
“Group”	the Company and all of its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Issuing Mandate”	a general and unconditional mandate proposed to be granted to the Directors at the AGM to exercise the power of the Company to allot, issue and deal with additional Shares of not exceeding 20% of the total number of issued Shares as at the date of passing of the proposed ordinary resolution as set out in the notice of the AGM
“Latest Practicable Date”	11 July 2018, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained in this circular
“Listing”	listing of the Shares on the Main Board of the Stock Exchange

## DEFINITIONS

“Listing Date”	11 March 2016, being the date on which the Shares were listed and from which dealings therein were permitted to take place on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China (for the purpose of this circular, excluding Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan)
“Repurchase Mandate”	a general and unconditional mandate proposed to be granted to the Directors at the AGM to exercise the power of the Company to repurchase Shares of not exceeding 10% of the total number of issued Shares as at the date of passing of the proposed ordinary resolution as set out in the notice of the AGM
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	ordinary share(s) in the share capital of the Company with par value of HK\$0.00001 each
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed thereto under the Listing Rules
“substantial shareholder(s)”	has the meaning ascribed thereto under the Listing Rules
“Takeovers Code”	the Code on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission, as amended from time to time
“HK\$”	Hong Kong dollar, the lawful currency of Hong Kong
“%”	per cent.

**LETTER FROM THE BOARD**



**Union Medical Healthcare Limited**  
**香港醫思醫療集團有限公司\***  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2138)**

*Executive Directors:*

Tang Chi Fai (*Chairman and  
Chief Executive Officer*)  
Lee Gabriel  
Luk Kun Shing Ben  
Yeung Chin Wan

*Independent non-executive Directors:*

Ma Ching Nam  
Look Andrew  
Lam Chi Hang Josekin

*Registered office:*

Cricket Square, Hutchins Drive  
PO Box 2681,  
Grand Cayman KY1-1111  
Cayman Islands

*Principal place of business:*

Suite 7–9, L21,  
Langham Place Office Tower,  
8 Argyle Street,  
Mong Kok,  
Hong Kong

18 July 2018

*To the Shareholders*

Dear Sir or Madam,

- (1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND  
REPURCHASE SHARES;**  
**(2) PROPOSED RE-ELECTION AND ELECTION OF DIRECTORS;**  
**AND**  
**(3) NOTICE OF ANNUAL GENERAL MEETING**

**INTRODUCTION**

The purpose of this circular is to provide you with information relating to the resolutions to be proposed, and if thought fit, to be approved at the AGM for, among other things, (i) the granting of the Issuing Mandate and the Repurchase Mandate to the Directors, and the extension of the Issuing Mandate by adding to it the total number of issued Shares repurchased by the Company under the Repurchase Mandate; and (ii) the re-election and election of Directors.

\* For identification purposes only

## **LETTER FROM THE BOARD**

### **PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES**

Pursuant to the ordinary resolutions of the Shareholder passed on 22 August 2017 at the annual general meeting of the Company held on 22 August 2017, general mandates were granted to the Directors to issue and repurchase Shares respectively. Such mandates will expire at the conclusion of the AGM. In order to give the Company the flexibility to issue and repurchase Shares if and when appropriate, the following ordinary resolutions will be proposed at the AGM to approve:

- (a) the granting of the Issuing Mandate to the Directors to exercise the power of the Company to allot, issue and deal with additional Shares of not exceeding 20% of the total number of issued Shares as at the date of passing of such resolution (i.e. a total of 196,744,989 Shares on the basis that the total number of issued Shares remains unchanged until the date of the AGM);
- (b) the granting of the Repurchase Mandate to the Directors to exercise the power of the Company to repurchase Shares on the Stock Exchange or any other stock exchange of which the Shares may be listed and which is recognised by the Securities and Futures Commission and the Stock Exchange of not exceeding 10% of the total number of issued Shares as at the date of passing of such resolution (i.e. a total of 98,372,494 Shares on the basis that the total number of issued Shares remains unchanged until the date of the AGM); and
- (c) the extension of the Issuing Mandate by adding the total number of Shares repurchased by the Company pursuant to the Repurchase Mandate.

An explanatory statement as required under Rule 10.06(1)(b) of the Listing Rules to provide the Shareholders with the requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Repurchase Mandate at the AGM is set out in Appendix I to this circular.

### **PROPOSED RE-ELECTION AND ELECTION OF DIRECTORS**

The Board currently consists of seven Directors.

According to Article 84 of the Articles of Association, at each annual general meeting of the Company, one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. Accordingly, Mr. Tang Chi Fai, Mr. Ma Ching Nam and Mr. Look Andrew shall retire from office at the AGM. All the above retiring Directors, being eligible, will offer themselves for re-election as Directors at the AGM.

## LETTER FROM THE BOARD

According to Article 83(3) of the Articles of Association, any Director appointed by the Board to fill a casual vacancy shall hold office until the first general meeting after his appointment and be subject to re-election at such meeting. Accordingly, Mr. Lam Chi Hang Josekin, who was appointed by the Board on 14 September 2017, shall hold office until the AGM and be subject to re-election at the AGM.

In addition, the Board has nominated Dr. Wang David Guowei (“**Dr. Wang**”) as a candidate of non-executive Director for the next term of the Board commencing on the date of the AGM. Accordingly, a resolution will be proposed at the AGM to elect Dr. Wang as a non-executive Director.

The biographical details of the retiring Directors and Dr. Wang proposed for re-election and election respectively at the AGM are set out in Appendix II to this circular.

### **AGM AND PROXY ARRANGEMENT**

The notice of the AGM is set out on pages 15 to 19 of this circular.

A form of proxy for use at the AGM is enclosed with this circular and such form of proxy is also published at the websites of Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company at [www.umhgp.com](http://www.umhgp.com). Whether or not you are able to attend the AGM, you are requested to complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return the completed form of proxy to the Hong Kong branch share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish and in such event, the form of proxy shall be deemed to be revoked.

Pursuant to Rule 13.39(4) of the Listing Rules and Article 66(1) of the Articles of Association, any vote of Shareholders at the AGM must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted by a show of hands. An announcement on the poll vote results will be published by the Company after the AGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

### **RECOMMENDATION**

The Board considers that the proposed granting/extension of the Issuing Mandate, granting of the Repurchase Mandate and re-election and election of Directors are in the interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM.

## LETTER FROM THE BOARD

### RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

### GENERAL

The Board confirms that to the best of their knowledge, information and belief having made all reasonable enquiries, as at the Latest Practicable Date, no Shareholder is required to abstain from voting on any resolution to be proposed at the AGM.

Your attention is drawn to the information set out in the appendices to this circular.

Yours faithfully  
For and on behalf of the Board of  
**Union Medical Healthcare Limited**  
**Lee Gabriel**  
*Executive Director*



*This appendix serves as an explanatory statement which contains all the information required under Rule 10.06(1)(b) of the Listing Rules for the Shareholders to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM in connection with the granting of the Repurchase Mandate.*

## **1. SHARE CAPITAL**

As at the Latest Practicable Date, the issued share capital of the Company comprised 983,724,948 Shares.

Subject to the passing of the ordinary resolution granting the Repurchase Mandate and on the basis that no further Shares are issued or repurchased by the Company after the Latest Practicable Date and up to the date of the AGM, the Directors will be authorised under the Repurchase Mandate to repurchase, on the Stock Exchange or any other stock exchange on which the Shares may be listed and recognised by the Securities and Futures Commission and the Stock Exchange, a maximum of 98,372,494 Shares, representing 10% of the total number of issued Shares as at the Latest Practicable Date, during the period in which the Repurchase Mandate is in force.

## **2. REASONS FOR THE REPURCHASE**

The Directors believe that the granting of the Repurchase Mandate is in the best interests of the Company and the Shareholders as a whole. An exercise of the Repurchase Mandate may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such a repurchase will benefit the Company and the Shareholders as a whole.

## **3. FUNDING OF REPURCHASE**

Repurchases would be funded entirely from the Company's available cash flow or working capital facilities which will be funds legally available under the laws of the Cayman Islands and/or any applicable laws, the Articles of Association and the Listing Rules as the case may be.

## **4. IMPACT OF REPURCHASE**

An exercise of the Repurchase Mandate in full may have a material adverse impact on the working capital and gearing position of the Company compared with those as at 31 March 2018, being the date of its latest published audited consolidated financial statements. The Directors do not, however, intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse impact on the working capital or gearing position of the Company which is in the opinion of the Directors are from time to time appropriate for the Company.

## 5. SHARE PRICES

The highest and lowest prices at which the Shares have been traded on the Stock Exchange in each of the previous twelve calendar months immediately prior to the Latest Practicable Date were as follows:

	<b>Highest</b> <i>HK\$</i>	<b>Lowest</b> <i>HK\$</i>
<b>2017</b>		
July	2.800	2.430
August	2.560	2.454
September	2.609	2.400
October	4.350	2.620
November	3.920	2.800
December	3.810	3.439
<b>2018</b>		
January	4.130	3.420
February	3.640	3.180
March	3.790	3.330
April	3.810	3.450
May	6.850	3.500
June	6.300	5.350
July (up to the Latest Practicable Date)	5.400	4.700

## 6. GENERAL

None of the Directors nor, to the best of their knowledge and having made all reasonable enquiries, any of their respective close associates, have any present intention to sell to the Company any of the Shares if the Repurchase Mandate is approved by the Shareholders at the AGM.

No core connected person of the Company has notified the Company that he/she/it has a present intention to sell any Shares to the Company, nor has undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders at the AGM.

## 7. UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the power of the Company to make repurchases of Shares pursuant to the Repurchase Mandate in accordance with the Listing Rules and all applicable laws of the Cayman Islands, and in accordance with the regulations set out in the memorandum and articles of association of the Company.

## 8. EFFECT OF TAKEOVERS CODE AND MINIMUM PUBLIC HOLDING

If a Shareholder's proportionate interest in the voting rights of the Company increases as a result of the Company repurchasing Shares pursuant to the Repurchase Mandate, such increase will be treated as an acquisition of voting rights for the purposes of Rule 32 of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert (as defined in the Takeovers Code), depending on the level of increase in the Shareholder's interests, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code. Save as the aforesaid, the Board is not aware of any consequences which would arise under the Takeovers Code as a result of an exercise of the Repurchase Mandate.

As at the Latest Practicable Date, to the best knowledge of the Company, Mr. Tang Chi Fai and Union Medical Care Holding Limited ("**Union Medical Care**") are the controlling shareholders of the Company (as defined in the Listing Rules), which were interested in 726,833,230 Shares, representing approximately 73.91% of the total issued share capital of the Company. Assuming exercise in full of the Repurchase Mandate by the Directors and there will be no change in the issued share capital of the Company or alterations to the existing shareholding of Mr. Tang Chi Fai and Union Medical Care, the aggregate percentage shareholding of Mr. Tang Chi Fai and Union Medical Care will be increased to approximately 82.09% of the total issued share capital of the Company. The Directors believe that such increase will not give rise to an obligation to make a mandatory offer under Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, the Directors have no present intention of exercising the Repurchase Mandate to such an extent that will result in the number of Shares in the hands of the public falling below the prescribed minimum percentage of 25% of the total issued share capital of the Company as required under the Rule 8.08 of the Listing Rules.

## 9. SHARE REPURCHASE MADE BY THE COMPANY

The Company had not repurchased any Shares (whether on the Stock Exchange or otherwise) during the financial year ended 31 March 2018 up to the Latest Practicable Date.

*This Appendix sets out details of the Directors proposed to be re-elected and elected as Directors at the AGM as below:*

**TANG Chi Fai (鄧志輝)**, aged 39, is the Chairman of the Board, the CEO, our executive Director and chairman of the Nomination Committee. He is a controlling Shareholder of the Company and he founded our Group on 23 November 2005. He is responsible for the overall management and strategic planning and development of our Group. Mr. Tang is also a director of various subsidiaries of the Company.

Mr. Tang has more than 16 years of experience in management and the aesthetic medical and medical healthcare industries. Mr. Tang has diversified experiences ranging from the initial establishment and business development of medical aesthetic clinics and beauty centres, the development of marketing strategies and maintenance of sales channels.

From September 1998 to May 2001, Mr. Tang attended the University of Hong Kong where he was enrolled in the bachelor of medicine and the bachelor of surgery programmes before deciding to pursue a different career path. From September 2001 to February 2005, Mr. Tang enrolled in the bachelor of business administration in accounting and finance at the University of Hong Kong and worked on a part-time basis before deciding to switch to full-time employment. Mr. Tang obtained Certificate IV in Training and Assessment from Northern Melbourne Institute of Technical and Further Education in September 2009 and the executive master of business administration degree from the University of Hull in January 2014. Mr. Tang is an Elizabeth Wordsworth Fellow at St. Hugh's College, University of Oxford.

Mr. Tang has entered into a service contract with the Company for an initial term of three (3) years, commencing from 11 March 2016, being the Listing Date and was supplemented by a supplemental agreement dated 9 July 2018, which shall be renewed as determined by the Board or the Shareholders of the Company. The appointment may be terminated by either party by giving at least three months' written notice to the other.

Pursuant to Mr. Tang's service contract (as supplemented), he is entitled to a remuneration of HK\$1,218,000 per annum and may be entitled to share options and/or discretionary bonus of a quantity to be determined by the Board at its discretion.

As at the Latest Practicable Date, Mr. Tang directly and wholly owns interests in Union Medical Care Holding Limited ("**Union Medical Care**"), which currently holds 721,231,230 ordinary shares of the Company, being 73.34% of total issued shares in the Company. Mr. Tang is also personally interested in 3,949,000 ordinary shares of the Company and Mr. Yau Ming Li, the spouse of Mr. Tang, owns 1,653,000 ordinary shares of the Company. Both Union Medical Care and Mr. Tang are the Controlling Shareholders of the Company. Ms. Yau Ming Li is the spouse of Mr. Tang and so Ms. Yau has deemed interests in the aggregate of 73.91% shareholding interests in the Company.

Save as disclosed above, Mr. Tang does not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. Tang does not hold any directorships and position in the listed public companies in the three years prior to the Latest Practicable Date.

Save as disclosed above, there are no other matters with respect to the appointment of Mr. Tang that need to be brought to the attention of the Shareholders and there is no other information relating to Mr. Tang that is required to be disclosed pursuant to the Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

**MA Ching Nam (馬清楠)**, aged 65, was appointed as our independent non-executive Director on 19 February 2016. Mr. Ma is also a member of each of the Audit Committee and the Remuneration Committee. Mr. Ma has been practising law for over 35 years. He was admitted as a solicitor in England and Wales, Hong Kong, Australia and Singapore. He currently serves as senior partner of Hastings & Co, Solicitors & Notaries, a law firm in Hong Kong. Mr. Ma is also a Notary Public, China Appointed Attesting Officer and Civil Celebrant. He was the president of the Hong Kong Society of Notaries from 2007 to 2013.

Mr. Ma currently serves as directors of Tai Sang Bank Limited, Heptacontinental group of companies, Ma Kam Ming Company Limited, Ma Kam Ming Charitable Foundation and Ma's Enterprises Company Limited. He is also an independent non-executive director of Time Watch Investments Limited which was listed on the Main Board of the Stock Exchange (Stock Code: 2033). Mr. Ma has also been a director and Vice Chairman of Po Leung Kuk since 2009 and 2014 respectively.

Mr. Ma is also a member of the Hospital Governing Committee of Grantham Hospital in Hong Kong, a member of the Standing Committee on Language Education and Research (SCOLAR) in Hong Kong, and a council member of Hong Kong St. John Ambulance. He has been appointed as a member of Political and Consultative Conference in Hunan Province, PRC. He was also a past Chairman of St. Paul's Co-educational College Alumni Association. Mr. Ma graduated from the University of Hull with a bachelor of science degree in economics with honours in 1977.

Mr. Ma has entered into a letter of appointment with the Company for an initial term of three (3) years, commencing from 11 March 2016, being the Listing Date, which shall be renewed as determined by the Board or the Shareholders of the Company. The appointment of each of the independent non-executive Directors may be terminated by either party by giving at least one month's written notice to the other.

Pursuant to Mr. Ma's letter of appointment signed in 2016, he is entitled to a remuneration of HK\$240,000 per annum and may be entitled to share options and/or discretionary bonus of a quantity to be determined by the Board at its discretion.

As at the Latest Practicable Date, Mr. Ma does not have any interests in the securities in the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Ma does not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. Ma does not hold any directorships and position in the listed public companies in the three years prior to the Latest Practicable Date.

Save as disclosed above, there are no other matters with respect to the appointment of Mr. Ma that need to be brought to the attention of the Shareholders and there is no other information relating to Mr. Ma that is required to be disclosed pursuant to the Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

**LOOK Andrew (陸東)**, aged 54, was appointed as our independent non-executive Director on 19 February 2016. Mr. Look is also a member of each of the Nomination Committee and the Remuneration Committee, as well as the chairman of the Audit Committee.

Mr. Look holds a bachelor of commerce degree from the University of Toronto and has over 25 years' experience in the equity investment analysis of Hong Kong and China stock markets. From 2000 to 2008, Mr. Look served in Union Bank of Switzerland (“UBS”) as the head of Hong Kong research, strategy and product. He was rated as the best Hong Kong strategist and best analyst by the Asiamoney magazine, a leading monthly financial and capital markets publication for corporate and finance readers and investors, in 2001, 2002, 2003, 2005, 2006 and 2007. Mr. Look is currently the Chief Investment Officer of the asset management business of Tou Rong Chang Fu Group Limited (Stock code: 850), a company listed on the Hong Kong Stock Exchange. Mr. Look is also currently an independent non-executive director of Hung Fook Tong Group Holdings Limited (Stock Code: 1446), Citic Resources Holdings Limited (Stock Code: 1205), Ka Shui International Holdings Limited (Stock Code: 822) and Cowell e Holdings Inc. (Stock code: 1415), all of which are listed on the Hong Kong Stock Exchange. He was an independent non-executive director of TCL Communication Technology Holdings Limited (a company delisted on the Hong Kong Stock Exchange on 30 September 2016) from September 2010 to September 2016 and an independent non-executive director of Man Sang Jewellery Holdings Limited (Stock Code: 1466, a company listed on the Hong Kong Stock Exchange) from September 2014 to December 2016.

Mr. Look has entered into a letter of appointment with the Company for an initial term of three (3) years, commencing from 11 March 2016, being the Listing Date, which shall be renewed as determined by the Board or the Shareholders of the Company. The appointment of each of the independent non-executive Directors may be terminated by either party by giving at least one month's written notice to the other.

Pursuant to Mr. Look's letter of appointment signed in 2016, he is entitled to a remuneration of HK\$220,000 per annum and may be entitled to share options and/or discretionary bonus of a quantity to be determined by the Board at its discretion.

As at the Latest Practicable Date, Mr. Look does not have any interests in the securities in the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Look does not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. Look does not hold any directorships and position in the listed public companies in the three years prior to the Latest Practicable Date.

Save as disclosed above, there are no other matters with respect to the appointment of Mr. Look that need to be brought to the attention of the Shareholders and there is no other information relating to Mr. Look that is required to be disclosed pursuant to the Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

**LAM Chi Hang Josekin (林知行)**, aged 38, was appointed as our independent non-executive Director on 14 September 2017. Mr. Lam is also a member of each of the Audit Committee and the Nomination Committee, as well as the chairman of the Remuneration Committee.

Mr. Lam has extensive knowledge and over 17 years of experience in business consultancy and financial industry. Prior to setting up and running his own business consultancy and real estate brokerage firms in 2009 and 2014 respectively, Mr. Lam was a consultant at Bain & Co, Inc, a management consulting company. Mr. Lam was the acting chief executive officer of Sanook.com, a subsidiary of Tencent Holdings Limited (“**Tencent**”), a company listed on the Main Board of the Stock Exchange (Stock Code: 700). Prior to joining the Group, Mr. Lam last held the position as a director of strategy department of Tencent. Mr. Lam graduated from Tufts University with a Bachelor of Arts degree in Quantitative Economics and International Relations in May 2001 and the University of Chicago Booth School of Business with a Master of Business Administration in June 2007.

Mr. Lam has entered into a letter of appointment with the Company for an initial term of two years commencing from 14 September 2017. Mr. Lam shall hold office until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that meeting. He is subject to the retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

Pursuant to the letter of appointment entered into between the Company and Mr. Lam, the Director’s fee of Mr. Lam will be HK\$120,000 per annum which is determined with reference to his expected duties and responsibilities and the prevailing market conditions.

As at the Latest Practicable Date, Mr. Lam does not have any interests in the securities in the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Lam does not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. Lam does not hold any directorships and position in the listed public companies in the three years prior to the Latest Practicable Date.

Save as disclosed above, there are no other matters with respect to the appointment of Mr. Lam that need to be brought to the attention of the Shareholders and there is no other information relating to Mr. Lam that is required to be disclosed pursuant to the Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

**Dr. Wang David Guowei (王國璋)**, aged 56, has over 10 years of experience in the medical industry. Dr. Wang is the senior managing director of Asia at OrbiMed Advisors LLC, an investment fund with a focus on healthcare industry, where he has worked from August 2011. Dr. Wang was a director of Response Biomedical Corp. (Stock Code: RBM), a company listed on the Toronto Stock Exchange, from October 2011 to May 2015. From April 2006 to July 2011, he served as managing director at WI Harper Group, responsible for investment activities in life sciences and healthcare areas. From March 2010 to July 2012, he served on the board of directors of Edan instruments, Inc. (a company listed in the Shenzhen Stock Exchange, stock code: 300206), a provider of advanced electronic medical equipments where he also served on both the audit committee and strategic committee. Dr. Wang is now serving on the board of directors of Suzhou Medical System Technology Co., Ltd. (a company listed in Shanghai Stock Exchange, stock code: 603990), serving on the boards of directors of Amoy Diagnostics Co., Ltd. (a company listed in Shenzhen Stock Exchange, stock code: 300685), and serving on the boards of directors of AK Medical Holdings Limited (a company listed in Hong Kong Stock Exchange, stock code: 1789).

Dr. Wang received his doctorate in developmental biology from California Institute of Technology in June 1995. He received his bachelor degree in medicine from Beijing Medical University (北京醫科大學) (currently known as Peking University Health Science Centre (北京大學醫學部)) in July 1986.

Dr. Wang's term of service as a non-executive Director commences from the date of AGM and will be for a term of three years if he is elected as a Director at the AGM. Under an authorization to be granted by the Shareholders at the AGM, the Company will enter into a service contract with Dr. Wang. His remuneration will be determined in accordance with the terms and conditions of the said service contract having regard to his duties and responsibilities with the Company, the Company's remuneration policy, the Company's performance and profitability.

As at the Latest Practicable Date, Dr. Wang does not have any interests in the securities in the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Dr. Wang does not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Dr. Wang does not hold any directorships and position in the listed public companies in the three years prior to the Latest Practicable Date.

Save as disclosed above, there are no other matters with respect to the appointment of Dr. Wang that need to be brought to the attention of the Shareholders and there is no other information relating to Dr. Wang that is required to be disclosed pursuant to the Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.



## NOTICE OF AGM



### **Union Medical Healthcare Limited**

**香港醫思醫療集團有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2138)**

### **NOTICE OF ANNUAL GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that an annual general meeting of Union Medical Healthcare Limited (the “**Company**”) will be held at Level 53, Langham Place Office Tower, 8 Argyle Street, Mong Kok, Hong Kong on Monday, 20 August 2018 at 10:00 a.m. for the following purposes:

1. To consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors (the “**Directors**”) and independent auditor of the Company for the year ended 31 March 2018;
2. (a) To consider and approve the declaration of a final dividend of HK5.0 cents per ordinary share of the Company (“**Share**”) for the year ended 31 March 2018;  
(b) To consider and approve the declaration of a special dividend of HK9.5 cents per ordinary share for the year ended 31 March 2018;
3. (a) To re-elect Mr. Tang Chi Fai as executive Director;  
(b) To re-elect Mr. Ma Ching Nam as independent non-executive Director;  
(c) To re-elect Mr. Look Andrew as independent non-executive Director;  
(d) To re-elect Mr. Lam Chi Hang Josekin as independent non-executive Director;  
(e) To elect Dr. Wang David Guowei as non-executive Director; and  
(f) To authorize the board of Directors to fix the Directors’ remuneration.
4. To re-appoint KPMG, Certified Public Accountants as the auditors of the Company and to authorize the board of Directors to fix their remuneration;

\* *For identification purposes only*

## NOTICE OF AGM

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

**“THAT:**

- (a) subject to paragraph (c) below, pursuant to the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the exercise by the Directors during the Relevant Period (as defined below) of the power of the Company to allot, issue and otherwise deal with additional shares of the Company (the “**Shares**”) or securities convertible into Shares and to make or grant offers, agreements and options (including but not limited to warrants, options, bonds, notes, securities and debentures conferring the rights to subscribe for or otherwise receive Shares), which might require the exercise of such powers be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall authorise the Directors during the Relevant Period to make or grant offers, agreements and/or options which might require the exercise of such powers after the end of the Relevant Period;
- (c) the total number of Shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to:
  - (i) a Rights Issue (as defined below); or
  - (ii) the grant of options or rights to acquire Shares or an issue of Shares upon exercise of options or rights granted under the existing share option scheme of the Company or similar arrangement for the time being adopted and approved by the shareholders of the Company; or
  - (iii) any scrip dividend or similar arrangements providing for the allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company in force from time to time (the “**Articles**”); or
  - (iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any options, warrants or similar rights granted by the Company or any securities which are convertible into Shares,

shall not exceed 20% of the total number of Shares in issue as at the date of the passing of this resolution and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and

## NOTICE OF AGM

(d) for the purposes of this resolution:

“**Relevant Period**” means the period from the date of the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any other applicable laws including, without limitation, laws of the Cayman Islands to be held; and
- (iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the Directors by this resolution;

“**Rights Issue**” means an offer of Shares, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of Shares on the register on a fixed record date in proportion to their then holdings of Shares (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction outside Hong Kong or any recognised regulatory body or any stock exchange outside Hong Kong).”

6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT:**

- (a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as defined below) of the power of the Company to purchase the Shares on the Stock Exchange or any other stock exchange on which the Shares may be listed and recognised by the Securities and Futures Commission and the Stock Exchange for such purpose, subject to and in accordance with all applicable laws and the requirements of the Listing Rules or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the total number of Shares which may be purchased by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period shall not exceed 10% of the total number of Shares in issue as at the date of the passing of this resolution and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and

## NOTICE OF AGM

(c) for the purposes of this resolution:

“**Relevant Period**” means the period from the date of the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company, the Companies Law of the Cayman Islands or any other applicable laws to be held; and
- (iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the Directors by this resolution.”

7. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT** conditional upon the passing of the resolutions no. 5 and 6 set out in this notice of annual general meeting, the general mandate referred to in resolution no. 5 above be and is hereby extended by the addition to the total number of Shares which may be allotted or issued or agreed conditionally or unconditionally to be allotted or issued by the Directors pursuant to such general mandate of the number of Shares repurchased by the Company pursuant to the mandate referred to in the resolution no. 6 above, provided that such amount shall not exceed 10% of the total number of the issued share capital of the Company as at the date of passing of this resolution.”

Yours faithfully  
For and on behalf of the Board of  
**Union Medical Healthcare Limited**  
**Lee Gabriel**  
*Executive Director*

Hong Kong, 18 July 2018

*Notes:*

1. All resolutions (except for procedural and administrative matters) at the meeting will be taken by poll pursuant to the Listing Rules. The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.
2. Any shareholders of the Company entitled to attend and vote at the above meeting is entitled to appoint another person as his proxy to attend and vote on his behalf. A shareholder who is the holder of two or more Shares may appoint more than one proxy to represent him and vote on his behalf at the above meeting. A proxy need not be a shareholder of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed.

## NOTICE OF AGM

3. In case of joint registered holders of a Share, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the vote(s) of the other joint holder(s) and for this purpose seniority shall be determined by the order in which the names stand in the register of shareholders of the Company in respect of the Shares.
4. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the offices of the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time for holding the annual general meeting or any adjournment thereof. Completion and return of a form of proxy will not preclude a shareholder of the Company from attending in person and voting at the annual general meeting or any adjournment thereof should he so wish and in such event, the form of proxy shall be deemed to be revoked.
5. To be entitled to attend and vote at the AGM, all transfer documents accompanied by the relevant share certificates must be lodged with the branch share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration no later than 4:30 p.m. on 14 August 2018.
6. The register of shareholders of the Company will be closed on 24 August 2018 to 28 August 2018 in order to qualify for the proposed final dividend and special dividend. All transfers of shares accompanied by the relevant Share certificates and transfer forms must be lodged with the branch share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration no later than 4:30 p.m. on 23 August 2018.
7. If a black rainstorm warning signal is in force or a tropical cyclone warning signal number 8 or above remains hoisted at 8:00 a.m. on 20 August 2018, the above meeting will be postponed. Shareholders of the Company are requested to read the website of the Company at [www.umhgp.com](http://www.umhgp.com) for details of alternative meeting arrangements. If shareholders of the Company have any queries concerning the alternative meeting arrangements, please call the Company at (852) 3975 4798 during business hours from 9:30 a.m. to 6:30 p.m. on Monday to Friday, excluding public holidays.
8. The above meeting will be held as scheduled when an amber or red rainstorm warning signal is in force.
9. Shareholders of the Company should make their own decision as to whether they would attend the above meeting under bad weather conditions bearing in mind their own situation and if they should choose to do so, they are advised to exercise care and caution.

*As at the date of this notice, the Board comprises four executive directors, namely Mr. Tang Chi Fai, Mr. Lee Gabriel, Mr. Luk Kun Shing Ben and Mr. Yeung Chin Wan, and three independent non-executive directors, Mr. Ma Ching Lam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.*